𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)

✍ Scribed by W. Sandborn; J.-F. Colombel; R. Enns; B. Feagan; S. Hanauer; I. Lawrance; R. Panaccione; M. Sanders; S. Schreiber; S. Targan; S. van Deventer; P. Rutgeerts

Book ID
119757859
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
45 KB
Volume
127
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy
✍ Wolfgang Holtmeier; Stefan Zeuzem; Jan Preiβ; Wolfgang Kruis; Stephan Böhm; Chri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views

Background: Complementary therapies are frequently used by patients with inflammatory bowel disease (IBD). The aim of this study was to evaluate the efficacy and safety of long-term therapy with a new Boswellia serrata extract (Boswelan, PS0201Bo) in maintaining remission in patients with Crohn's di